Jul 2026· Journal of Applied Pharmaceutical Research· Vol 14, pp. 20-37· 0 citations
TL;DR
S-SMEDDS constitute an established pharmaceutical platform that overcomes the drawbacks associated with liquid lipid drug delivery systems and position them to be the foundation for precision oral drug delivery.
Abstract
Background: Approximately 40% of marketed medicines and 70% of pipeline products exhibit poor aqueous solubility, leading to inconsistent oral bioavailability and impaired efficacy. S-SMEDDS represent a revolutionary approach for converting liquids into stable solid dosage forms. Methodology: Methods employed to prepare S-SMEDDs include adsorption onto carriers, spray drying, hot-melt extrusion, and freeze-drying. Characterization includes assessing self-emulsifying behavior, dynamic light scattering, powder diffraction, and thermal analysis. Results and Discussion: Depending on the drug's characteristics, the formulation composition, and the study conditions, S-SMEDDS can increase bioavailability by two to ten times. However, for some extremely lipophilic BCS Class II and IV pharmaceuticals, significantly greater benefits (up to ~50-fold) have been documented. Several investigations have demonstrated that S-SMEDDS exhibit better physical and chemical stability than liquid systems under ICH Q1A(R2) accelerated storage conditions due to reduced lipid mobility and a lower risk of phase separation. Applications extend to the treatment of cardiovascular, oncological, and endocrine disorders with improved pharmacodynamic efficacy. The multiple absorption mechanisms in S-SMEDDS include improved solubilization, reduced precipitation, lymphotropic delivery, and inhibition of efflux pumps. They demonstrate higher chemical and physical stability, precise dosing, and better patient adherence when compared to traditional liquid counterparts. Conclusion: S-SMEDDS constitute an established pharmaceutical platform that overcomes the drawbacks associated with liquid lipid drug delivery systems. Their high effectiveness, manufacturability, and compatibility with novel technologies such as three-dimensional printing and artificial intelligence position them to be the foundation for precision oral drug delivery.
Poor aqueous solubility remains the single most common cause of variable and incomplete oral absorption among new chemical entities, with a substantial proportion of marketed and pipeline molecules falling under Biopharmaceutics Classification System (BCS) classes II and IV. Self-nanoemulsifying drug delivery systems (...
Deepa Cherian and Dr. Rakesh Kumar Jat· International Journal of Adv...· 0 citations
Biopharmaceutics Classification System (BCS) Class II drugs are characterized by low aqueous solubility, which can limit dissolution and oral absorption. Zaltoprofen is a non-steroidal anti-inflammatory drug with a hydrophobic structure and limited aqueous solubility. Pharmaceutical cocrystallization offers a solid-sta...
Rajan Kumar, S. Tomar, Ram Babu Sharma Ram Babu Sharma· Journal of Drug Delivery and...· 0 citations
Oxiconazole nitrate-loaded nanospheres were successfully developed using the emulsification–solvent evaporation method to enhance the solubility and dissolution of oxiconazole nitrate, a Biopharmaceutics Classification System (BCS) Class II antifungal drug characterized by low aqueous solubility and good membrane perme...
Suyash Shashikant Ingle, A. Chavan, Vasundhara Somnath Patil et al.· International Journal of Sci...· 0 citations
Background/Objectives: Solid self-nanoemulsifying drug delivery systems (SNEDDS) prepared by adsorption onto porous carriers are widely used to improve the oral delivery of poorly water-soluble drugs. However, this approach is limited by increased dosing volume and incomplete drug release. This study aims to develop a...
Abdelrahman Y. Sherif, Mohammad A. Altamimi, E. Elzayat· Pharmaceutics· 0 citations
The developed SEDDS formulation increased solubility, dissolution, plasma exposure, and therapeutic effectiveness of IIIM-019, representing a promising carrier for oral administration of investigated anti-tubercular lead.
G. Paudwal, Rigzin Dolkar, Anjali Negi et al.· AAPS PharmSciTech· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.